|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2100052952 |
|
最近更新日期: Date of Last Refreshed on: |
2021-11-06 21:18:55 |
|
注册时间: Date of Registration: |
2021-11-06 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
中国粤西地区脑卒中注册研究 |
|
Public title: |
STroke REgiStry program in Yuexi diStrict of China (STRESS) |
|
注册题目简写: |
前瞻性多中心脑卒中注册研究 |
|
English Acronym: |
STRESS |
|
研究课题的正式科学名称: |
中国粤西地区脑卒中注册研究 |
|
Scientific title: |
STroke REgiStry program in Yuexi diStrict of China (STRESS) |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
廖耿 |
研究负责人: |
廖耿 |
|
Applicant: |
Liao Geng |
Study leader: |
Liao Geng |
|
申请注册联系人电话: Applicant telephone: |
13929703268 |
研究负责人电话: Study leader's telephone: |
13929703268 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
legendv@126.com |
研究负责人电子邮件: Study leader's E-mail: |
legendv@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国广东省茂名市为民路101号 |
研究负责人通讯地址: |
中国广东省茂名市为民路101号 |
|
Applicant address: |
101 Weimin Road, Maoming, Guangdong, China |
Study leader's address: |
101 Weimin Road, Maoming, Guangdong, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
茂名市人民医院神经内科 |
||
|
Applicant's institution: |
Department of Neurology, Maoming people's Hospital |
||
|
研究负责人所在单位: |
茂名市人民医院神经内科 |
||
|
Affiliation of the Leader: |
Department of Neurology, Maoming people's Hospital |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
PJ2021MI-K171-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
茂名市人民医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Maoming People's Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2021-09-27 00:00:00 |
||
|
伦理委员会联系人: |
王广文 |
||
|
Contact Name of the ethic committee: |
Wang Guangwen |
||
|
伦理委员会联系地址: |
广东省茂名市茂南区为民路101号大院 |
||
|
Contact Address of the ethic committee: |
No. 101, Weimin Road, Maonan District, Maoming City, Guangdong Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
茂名市人民医院神经内科 |
||||||||||||||||||||||
|
Primary sponsor: |
Department of Neurology, Maoming People's Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
中国广东省茂名市为民路101号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
101 Weimin Road, Maoming, Guangdong, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
茂名市人民医院高水平医院建设项目(项目编号:粤卫函 2018413) |
||||||||||||||||||||||
|
Source(s) of funding: |
2020 Special Funds of Science and Technology of Guangdong Province (2020S00050); The High-level Hospital Construction Research Project of Maoming People's Hospital (Yueweihan 2018413) |
||||||||||||||||||||||
|
Target disease: |
stroke |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
1建立基于标准诊断程序的区域人群的脑卒中病因分类队列。 2掌握该区域脑卒中流行病学特征。 3掌握该区域脑卒中患者的预后和预后影响因素。 4监测和评价脑卒中各种干预措施的疗效风险。 5收集合理设计脑卒中治疗措施的临床试验所必须的信息。 2.1.6进行脑卒中相关基础研究 |
||||||||||||||||||||||
|
Objectives of Study: |
1 Establish a cohort to classify the cause of stroke in regional populations based on standard diagnostic procedures. 2 To explore the epidemiological characteristics of stroke in local district. 3 To explore the prognosis and prognostic factors of stroke patients in this area. 4 Monitor and evaluate the curative effect risk of various interventions for stroke. 5 Collect information necessary for clinical trials to rationally design stroke treatment measures. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
(1)任何年龄段。(2)1周内发生的急性脑血管事件(符合WHO卒中诊断标准并经颅脑MRI/CT证实的脑梗死或颅内出血、神经功能缺损持续24小时以上)。(3)获取患者或合法授权亲属的知情同意。 |
||||||||||||||||||||||
|
Inclusion criteria |
(1) Any age. (2) Acute cerebrovascular events occurred within 1 week (cerebral infarction or intracranial hemorrhage, neurological deficits that meet the WHO diagnostic criteria for stroke and confirmed by cranial MRI/CT, and neurological deficits last for more than 24 hours). (3) Obtain the informed consent of the patient or legally authorized relatives |
||||||||||||||||||||||
|
排除标准: |
(1)难以确诊是否为卒中的患者。(3)无症状性脑卒中。(4)不同意参加本研究的患者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) It is difficult to diagnose whether the patient is a stroke. (3) Asymptomatic stroke. (4) Patients who do not agree to participate in this study. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2021-12-01 00:00:00至 To 2031-11-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2021-12-01 00:00:00 至 To 2030-11-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
非随机 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Derandomization |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
项目组根据研究进程择期选择具体方式公开原始数据 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
According to the progress of the research, raw research data should be made freely available to all researchers in specific ways |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据记录在卒中登记平台(电子采集和管理系统),由专门的研究人员收集及管理数据。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data are recorded on the stroke registration platform. Date are collected and managed by one researcher. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |